Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 30, 2009 02:00 ET | Source: Mateon Therapeutics

OXiGENE Reports Second Quarter 2009 Financial Results; Company Continues to Achieve Pipeline Progress With Strengthened Cash Position

SOUTH SAN FRANCISCO, Calif., July 30, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer...
July 24, 2009 02:00 ET | Source: Mateon Therapeutics

OXiGENE Announces Second Quarter 2009 Earnings Conference Call and Webcast

SOUTH SAN FRANCISCO, Calif., July 24, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer...
July 21, 2009 02:00 ET | Source: Mateon Therapeutics

OXiGENE Announces Closing of Registered Direct Offering

SOUTH SAN FRANCISCO, Calif., July 21, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer...
July 15, 2009 09:00 ET | Source: Mateon Therapeutics

OXiGENE to Raise $10 Million in Registered Direct Offering

WALTHAM, Mass., July 15, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye...
July 06, 2009 02:00 ET | Source: Mateon Therapeutics

OXiGENE Announces Agreement to Acquire Symphony ViDA, Including More Than $12 Million in Unrestricted Cash and All Rights to OXi4503 and ZYBRESTAT for Ophthalmology

SOUTH SAN FRANCISCO, Calif., July 6, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and...
June 25, 2009 02:00 ET | Source: Mateon Therapeutics

OXiGENE Initiates Phase 2 Trial of ZYBRESTAT for Ophthalmology

SOUTH SAN FRANCISCO, Calif., June 25, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that...
June 17, 2009 02:00 ET | Source: Mateon Therapeutics

OXiGENE Appoints Dr. Peter J. Langecker as Chief Development Officer

WALTHAM, Mass., June 17, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced the appointment of...
June 01, 2009 10:45 ET | Source: Mateon Therapeutics

OXiGENE Reports Positive Data From Phase 2 Trial of ZYBRESTAT in Platinum Resistant Ovarian Cancer At the 2009 ASCO Annual Meeting

WALTHAM, Mass., June 1, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye...
May 21, 2009 02:00 ET | Source: Mateon Therapeutics

OXiGENE Announces Clinical Data to be Presented At the 2009 Annual Meeting of the American Society of Clinical Oncology

WALTHAM, Mass., May 21, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
May 11, 2009 16:00 ET | Source: Mateon Therapeutics

OXiGENE Reports First Quarter 2009 Financial Results

WALTHAM, Mass., May 11, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...